

INTRAVITREAL BEVACIZUMAB (AVASTIN) TREATMENT COMPLICATED BY VITREOUS HEMORRHAGE

Retina

26, 275-278

DOI: [10.1097/00006982-200603000-00004](https://doi.org/10.1097/00006982-200603000-00004)

Citation Report

#	ARTICLE	IF	CITATIONS
1	New Pharmacologic Approaches to Therapy for Age-Related Macular Degeneration. <i>BioDrugs</i> , 2006, 20, 167-179.	2.2	37
2	Promising new treatments for neovascular age-related macular degeneration. <i>Expert Opinion on Investigational Drugs</i> , 2006, 15, 779-793.	1.9	68
3	Evaluating Central Corneal Thickness Measurements With Noncontact Optical Low-Coherence Reflectometry and Contact Ultrasound Pachymetry. <i>American Journal of Ophthalmology</i> , 2006, 142, 164-165.	1.7	15
4	Intravitreal Avastin: The Low Cost Alternative to Lucentis?. <i>American Journal of Ophthalmology</i> , 2006, 142, 141-143.	1.7	117
5	Absence of Histologic Retinal Toxicity of Intravitreal Bevacizumab in a Rabbit Model. <i>American Journal of Ophthalmology</i> , 2006, 142, 162-164.	1.7	103
6	Intravitreal Injection of Bevacizumab (Avastin) as Adjunctive Treatment of Proliferative Diabetic Retinopathy. <i>American Journal of Ophthalmology</i> , 2006, 142, 685-688.	1.7	147
7	Retinal Vascular Abnormalities and Prevalence of Age-related Macular Degeneration in Adult Chinese: The Beijing Eye Study. <i>American Journal of Ophthalmology</i> , 2006, 142, 688-689.	1.7	28
8	Intravitreal Bevacizumab for Choroidal Neovascularization Caused by AMD (IBeNA Study): Results of a Phase 1 Dose-Escalation Study. , 2006, 47, 4569.		158
9	EVALUATION OF IN VITRO EFFECTS OF BEVACIZUMAB (AVASTIN) ON RETINAL PIGMENT EPITHELIAL, NEUROSENSORY RETINAL, AND MICROVASCULAR ENDOTHELIAL CELLS. <i>Retina</i> , 2006, 26, 512-518.	1.0	107
10	NEOVASCULAR GROWTH FOLLOWING PHOTODYNAMIC THERAPY FOR CHOROIDAL HEMANGIOMA AND NEOVASCULAR REGRESSION AFTER INTRAVITREOUS INJECTION OF TRIAMCINOLONE. <i>Retina</i> , 2006, 26, 693-697.	1.0	13
11	SILICONE OIL DROPLETS FOLLOWING INTRAVITREAL INJECTION. <i>Retina</i> , 2006, 26, 701-703.	1.0	9
12	BIMANUAL VITREOUS SURGERY WITH SLIT-BEAM ILLUMINATION AND A MULTICOATED CONTACT LENS. <i>Retina</i> , 2006, 26, 708-709.	1.0	1
13	CHOROIDAL NEOVASCULAR MEMBRANE ASSOCIATED WITH MELANOCYTOMA OF THE OPTIC NERVE. <i>Retina</i> , 2006, 26, 703-704.	1.0	1
14	CONGENITAL SIMPLE HAMARTOMA OF THE RETINAL PIGMENT EPITHELIUM: OPTICAL COHERENCE TOMOGRAPHY AND ANGIOGRAPHY FEATURES. <i>Retina</i> , 2006, 26, 704-706.	1.0	4
15	NEOVASCULAR GROWTH FOLLOWING PHOTODYNAMIC THERAPY FOR CHOROIDAL HEMANGIOMA AND NEOVASCULAR REGRESSION AFTER INTRAVITREOUS INJECTION OF TRIAMCINOLONE. <i>Retina</i> , 2006, 26, 693-697.	1.0	14
16	SILICONE OIL DROPLETS FOLLOWING INTRAVITREAL INJECTION. <i>Retina</i> , 2006, 26, 701-703.	1.0	61
17	EVALUATION OF ANTERIOR CHAMBER INFLAMMATORY ACTIVITY IN EYES TREATED WITH INTRAVITREAL BEVACIZUMAB. <i>Retina</i> , 2006, 26, 877-881.	1.0	58
18	USE OF INTRAVITREAL BEVACIZUMAB AS A PREOPERATIVE ADJUNCT FOR TRACTIONAL RETINAL DETACHMENT REPAIR IN SEVERE PROLIFERATIVE DIABETIC RETINOPATHY. <i>Retina</i> , 2006, 26, 699-700.	1.0	176

#	ARTICLE	IF	CITATIONS
19	INTRAVITREAL BEVACIZUMAB (AVASTIN) FOR PERSISTENT NEW VESSELS IN DIABETIC RETINOPATHY (IBEPE) Tj ET Oq 0 0 0 rgBT /Overloc	1.0	237
20	Expanding Treatment Options in Age-related Macular Degeneration. <i>International Ophthalmology Clinics</i> , 2006, 46, 123-129.	0.3	9
21	EASY AND EFFECTIVE WAY TO REMOVE RESIDUAL SILICONE OIL DROPLETS IN PHAKIC PATIENTS. <i>Retina</i> , 2006, 26, 697-699.	1.0	1
22	CORNEAL GRAFT DEHISCENCE DURING PNEUMATIC RETINOPEXY. <i>Retina</i> , 2006, 26, 707.	1.0	2
23	BIMANUAL VITREOUS SURGERY WITH SLIT-BEAM ILLUMINATION AND A MULTICOATED CONTACT LENS. <i>Retina</i> , 2006, 26, 708-709.	1.0	3
24	CHOROIDAL NEOVASCULAR MEMBRANE ASSOCIATED WITH MELANOCYTOMA OF THE OPTIC NERVE. <i>Retina</i> , 2006, 26, 703-704.	1.0	5
25	CONGENITAL SIMPLE HAMARTOMA OF THE RETINAL PIGMENT EPITHELIUM: OPTICAL COHERENCE TOMOGRAPHY AND ANGIOGRAPHY FEATURES. <i>Retina</i> , 2006, 26, 704-706.	1.0	22
26	INTRAVITREAL BEVACIZUMAB (AVASTIN) THERAPY FOR PERSISTENT DIFFUSE DIABETIC MACULAR EDEMA. <i>Retina</i> , 2006, 26, 999-1005.	1.0	423
27	Short-term results of intravitreal bevacizumab (Avastin) on anterior segment neovascularization in neovascular glaucoma. <i>Acta Ophthalmologica</i> , 2006, 84, 556-557.	0.4	83
29	Opaque coating of an intraocular lens and regression of iris neovascularization following injection of triamcinolone acetonide into the anterior chamber. <i>Clinical and Experimental Ophthalmology</i> , 2006, 34, 803-805.	1.3	3
30	Rapid resolution of severe disc new vessels in proliferative diabetic retinopathy following a single intravitreal injection of bevacizumab (Avastin). <i>Clinical and Experimental Ophthalmology</i> , 2006, 34, 802-803.	1.3	40
31	Evolving European guidance on the medical management of neovascular age related macular degeneration. <i>British Journal of Ophthalmology</i> , 2006, 90, 1188-1196.	2.1	62
32	The International Intravitreal Bevacizumab Safety Survey: using the internet to assess drug safety worldwide. <i>British Journal of Ophthalmology</i> , 2006, 90, 1344-1349.	2.1	502
33	Some ethical considerations for the "off-label" use of drugs such as Avastin. <i>British Journal of Ophthalmology</i> , 2006, 90, 1218-1219.	2.1	13
34	Is intravitreal bevacizumab (Avastin) safe?. <i>British Journal of Ophthalmology</i> , 2006, 90, 1333-1334.	2.1	25
35	Antiproliferative and cytotoxic properties of bevacizumab on different ocular cells. <i>British Journal of Ophthalmology</i> , 2006, 90, 1316-1321.	2.1	109
36	Rapid regression of disc and retinal neovascularization in a case of Eales disease after intravitreal bevacizumab. <i>Canadian Journal of Ophthalmology</i> , 2007, 42, 335-336.	0.4	7
37	Intravitreal Bevacizumab for Filtering Surgery. <i>Ophthalmic Research</i> , 2007, 39, 121-122.	1.0	65

#	ARTICLE	IF	CITATIONS
38	Bevacizumab for ophthalmic diseases. Expert Review of Ophthalmology, 2007, 2, 369-378.	0.3	4
39	Short-Term Results of Intravitreal Bevacizumab for Macular Edema with Retinal Vein Obstruction and Diabetic Macular Edema. Journal of Ocular Pharmacology and Therapeutics, 2007, 23, 387-394.	0.6	17
40	Vitreous hemorrhage: a discussion of etiologies, controversies and current and future therapeutics. Expert Review of Ophthalmology, 2007, 2, 249-254.	0.3	2
42	Pharmacotherapies for Diabetic Retinopathy: Present and Future. Experimental Diabetes Research, 2007, 2007, 1-8.	3.8	18
43	Role of Intravitreal Bevacizumab in Neovascular Glaucoma. Journal of Ocular Pharmacology and Therapeutics, 2007, 23, 487-491.	0.6	80
44	Ranibizumab (Lucentis) versus bevacizumab (Avastin): modelling cost effectiveness. British Journal of Ophthalmology, 2007, 91, 1244-1246.	2.1	132
45	New pharmacologic approaches to treating diabetic retinopathy. American Journal of Health-System Pharmacy, 2007, 64, S15-S21.	0.5	18
46	Management of Diabetic Retinopathy. JAMA - Journal of the American Medical Association, 2007, 298, 902.	3.8	731
47	Inhibition of experimental corneal neovascularisation by bevacizumab (Avastin). British Journal of Ophthalmology, 2007, 91, 804-807.	2.1	200
48	Preclinical Safety Evaluation of Intravitreal Injection of Full-Length Humanized Vascular Endothelial Growth Factor Antibody in Rabbit Eyes. Investigative Ophthalmology and Visual Science, 2007, 48, 1773-1781.	3.3	117
49	Vascular Endothelial Growth Factor in Aqueous Humor Before and After Intravitreal Injection of Bevacizumab in Eyes With Diabetic Retinopathy. JAMA Ophthalmology, 2007, 125, 1363.	2.6	80
50	STANDARDIZED VISUAL ACUITY RESULTS ASSOCIATED WITH PRIMARY VERSUS SECONDARY BEVACIZUMAB (AVASTIN) TREATMENT FOR CHOROIDAL NEOVASCULARIZATION IN AGE-RELATED MACULAR DEGENERATION. Retina, 2007, 27, 701-706.	1.0	39
51	RETINAL PIGMENT EPITHELIAL TEARS AFTER INTRAVITREAL BEVACIZUMAB INJECTION FOR NEOVASCULAR AGE-RELATED MACULAR DEGENERATION. Retina, 2007, 27, 541-551.	1.0	160
52	TRIPLE THERAPY FOR CHOROIDAL NEOVASCULARIZATION DUE TO AGE-RELATED MACULAR DEGENERATION. Retina, 2007, 27, 133-140.	1.0	194
53	INTRAVITREAL BEVACIZUMAB (AVASTIN) INJECTION ALONE OR COMBINED WITH TRIAMCINOLONE VERSUS MACULAR PHOTOCOAGULATION AS PRIMARY TREATMENT OF DIABETIC MACULAR EDEMA. Retina, 2007, 27, 1187-1195.	1.0	119
54	REBOUND MACULAR EDEMA FOLLOWING BEVACIZUMAB (AVASTIN) THERAPY FOR RETINAL VENOUS OCCLUSIVE DISEASE. Retina, 2007, 27, 426-431.	1.0	121
55	Safety Profile of Bevacizumab on Cultured Human Corneal Cells. Cornea, 2007, 26, 977-982.	0.9	94
58	Intravitreal Bevacizumab (Avastin) Injection for Neovascular Glaucoma. Journal of Glaucoma, 2007, 16, 437-439.	0.8	98

#	ARTICLE	IF	CITATIONS
59	RETINAL PIGMENT EPITHELIUM TEARS AFTER INTRAVITREAL INJECTION OF BEVACIZUMAB (AVASTIN) FOR NEOVASCULAR AGE-RELATED MACULAR DEGENERATION. <i>Retina</i> , 2007, 27, 535-540.	1.0	62
60	Ocular Neovascularization: Basic Mechanisms and Therapeutic Advances. <i>Survey of Ophthalmology</i> , 2007, 52, S3-S19.	1.7	118
61	Primary Intravitreal Bevacizumab (Avastin) for Diabetic Macular Edema. <i>Ophthalmology</i> , 2007, 114, 743-750.	2.5	318
62	Pharmacokinetics of Intravitreal Bevacizumab (Avastin). <i>Ophthalmology</i> , 2007, 114, 855-859.	2.5	636
63	Pharmacokinetics of Intravitreal Ranibizumab (Lucentis). <i>Ophthalmology</i> , 2007, 114, 2179-2182.	2.5	497
64	The Neuronal Influence on Retinal Vascular Pathology. , 2007, , 108-120.		1
65	Changes in Select Redox Proteins of the Retinal Pigment Epithelium in Age-related Macular Degeneration. <i>American Journal of Ophthalmology</i> , 2007, 143, 607-615.e2.	1.7	143
66	Bevacizumab (Avastin) for Diabetic Macular Edema in Previously Vitrectomized Eyes. <i>American Journal of Ophthalmology</i> , 2007, 144, 124-126.	1.7	122
67	Peripheral Retinopathy and Maculopathy in High-dose Tamoxifen Therapy. <i>American Journal of Ophthalmology</i> , 2007, 144, 126-128.	1.7	99
68	Intravitreal Bevacizumab Therapy for Neovascular Age-related Macular Degeneration with Large Submacular Hemorrhage. <i>American Journal of Ophthalmology</i> , 2007, 144, 886-892.e2.	1.7	91
69	Novel role of erythropoietin in proliferative diabetic retinopathy. <i>Diabetes Research and Clinical Practice</i> , 2007, 77, S62-S64.	1.1	50
70	Primary intravitreal bevacizumab for the management of pseudophakic cystoid macular edema. <i>Journal of Cataract and Refractive Surgery</i> , 2007, 33, 2098-2105.	0.7	51
71	Retinal and choroidal microangiopathies: Therapeutic opportunities. <i>Microvascular Research</i> , 2007, 74, 131-144.	1.1	60
72	Vitrectomy: when things go wrong. <i>Expert Review of Ophthalmology</i> , 2007, 2, 645-660.	0.3	1
73	The Therapeutic Potential of VEGF Inhibition in Diabetic Microvascular Complications. <i>American Journal of Cardiovascular Drugs</i> , 2007, 7, 393-398.	1.0	30
74	The Effects of Intravitreal Bevacizumab on Retinal Neovascular Membrane and Normal Capillaries in Rabbits. , 2007, 48, 5708.		77
75	Intravitreal Avastin for choroidal neovascularisation in pathological myopia: the controversy continues. <i>British Journal of Ophthalmology</i> , 2007, 91, 128-130.	2.1	17
76	Neovascular glaucoma. <i>Progress in Retinal and Eye Research</i> , 2007, 26, 470-485.	7.3	194

#	ARTICLE	IF	CITATIONS
77	Intravitreal bevacizumab (Avastin) in combination with verteporfin photodynamic therapy for choroidal neovascularization associated with age-related macular degeneration (IBeVe Study). Graefe's Archive for Clinical and Experimental Ophthalmology, 2007, 245, 1273-1280.	1.0	57
78	Electrophysiological and structural assessment of the central retina following intravitreal injection of bevacizumab for treatment of macular edema. Documenta Ophthalmologica, 2008, 116, 129-135.	1.0	33
79	Intravitreal anti-VEGF for diabetic retinopathy: hopes and fears for a new therapeutic strategy. Diabetologia, 2008, 51, 1574-1580.	2.9	188
81	Injection of intravitreal bevacizumab (Avastin) as a preoperative adjunct before vitrectomy surgery in the treatment of severe proliferative diabetic retinopathy (PDR). Graefe's Archive for Clinical and Experimental Ophthalmology, 2008, 246, 837-842.	1.0	162
82	Prognostic factors for visual outcome after intravitreal bevacizumab for macular edema due to branch retinal vein occlusion. Graefe's Archive for Clinical and Experimental Ophthalmology, 2008, 246, 1241-1247.	1.0	98
83	Vascular endothelial growth factor in fellow eyes of eyes injected with intravitreal bevacizumab. Graefe's Archive for Clinical and Experimental Ophthalmology, 2008, 246, 1379-1381.	1.0	30
84	Intravitreal injection of bevacizumab and gas for diabetic premacular hemorrhage with active fibrovascular proliferation. Graefe's Archive for Clinical and Experimental Ophthalmology, 2008, 246, 1547-1551.	1.0	7
85	Intravitreal bevacizumab in active progressive proliferative diabetic retinopathy. Graefe's Archive for Clinical and Experimental Ophthalmology, 2008, 246, 1699-1705.	1.0	125
86	Rapid regression of retinal hemorrhage and neovascularization in a case of familial exudative vitreoretinopathy treated with intravitreal bevacizumab. Graefe's Archive for Clinical and Experimental Ophthalmology, 2008, 246, 1787-1789.	1.0	27
87	Intravitreal bevacizumab in recurrent diabetic vitreous haemorrhage after vitrectomy. Acta Ophthalmologica, 2008, 86, 231-232.	0.6	17
88	Intravitreal bevacizumab (Avastin [®]) in proliferative diabetic retinopathy. Acta Ophthalmologica, 2008, 86, 683-687.	0.6	55
89	Panretinal photocoagulation versus PRP plus intravitreal bevacizumab for high-risk proliferative diabetic retinopathy (IBeHi study). Acta Ophthalmologica, 2008, 86, 385-389.	0.6	113
90	Intravitreal bevacizumab for vitreous haemorrhage. Acta Ophthalmologica, 2008, 86, 585-586.	0.6	17
91	Avastin as an adjunct to vitrectomy in the management of severe proliferative diabetic retinopathy: a prospective case series. Clinical and Experimental Ophthalmology, 2008, 36, 449-454.	1.3	31
92	Diabetic retinopathy: A comprehensive review. Indian Journal of Medical Sciences, 2008, 62, 500.	0.1	52
93	Absence of intravitreal bevacizumab-induced neuronal toxicity in the retina. NeuroToxicology, 2008, 29, 1131-1135.	1.4	32
94	Efficacy of intravitreal bevacizumab in treating postoperative pseudophakic cystoid macular edema. Journal of Cataract and Refractive Surgery, 2008, 34, 70-75.	0.7	95
96	Subconjunctival Bevacizumab Injection for Corneal Neovascularization in Recurrent Pterygium. Current Eye Research, 2008, 33, 23-28.	0.7	112

#	ARTICLE	IF	CITATIONS
97	Tractional retinal detachment following intravitreal bevacizumab (Avastin) in patients with severe proliferative diabetic retinopathy. <i>British Journal of Ophthalmology</i> , 2008, 92, 213-216.	2.1	364
98	Proliferative Diabetic Retinopathy. , 2008, , 29-65.		20
99	Interventions for diabetic macular oedema: a systematic review of the literature. <i>British Journal of Ophthalmology</i> , 2008, 92, 1581-1590.	2.1	38
100	Intravitreal bevacizumab for the treatment of macular oedema secondary to branch retinal vein occlusion. <i>British Journal of Ophthalmology</i> , 2008, 92, 351-355.	2.1	93
101	The Treatment of Choroidal Neovascularisations with Intravitreal Injections of Bevacizumab (Avastin®). <i>Klinische Monatsblätter Für Augenheilkunde</i> , 2008, 225, 380-384.	0.3	6
102	Regression of a Subfoveal Choroidal Metastasis of Colorectal Carcinoma After Intravitreal Bevacizumab Treatment. <i>JAMA Ophthalmology</i> , 2008, 126, 1311.	2.6	44
103	Emerging drugs for diabetic retinopathy. <i>Expert Opinion on Emerging Drugs</i> , 2008, 13, 675-694.	1.0	29
105	Effect of Bevacizumab on Inflammation and Proliferation in Human Choroidal Neovascularization. <i>JAMA Ophthalmology</i> , 2008, 126, 782.	2.6	42
106	OFF-LABEL USE OF INTRAVITREAL BEVACIZUMAB (AVASTIN) FOR SALVAGE TREATMENT IN PROGRESSIVE THRESHOLD RETINOPATHY OF PREMATURITY. <i>Retina</i> , 2008, 28, S13-S18.	1.0	126
107	LONG-TERM EFFECT OF INTRAVITREAL BEVACIZUMAB (AVASTIN) IN PATIENTS WITH CHRONIC DIFFUSE DIABETIC MACULAR EDEMA. <i>Retina</i> , 2008, 28, 1053-1060.	1.0	152
108	INCIDENCE OF ACUTE ONSET ENDOPHTHALMITIS FOLLOWING INTRAVITREAL BEVACIZUMAB (AVASTIN) INJECTION. <i>Retina</i> , 2008, 28, 564-567.	1.0	145
109	Effect of Intracameral Bevacizumab Injection on Corneal Endothelium in Rabbits. <i>Cornea</i> , 2008, 27, 1151-1155.	0.9	22
110	INTRAVITREAL BEVACIZUMAB (AVASTIN) PREVENTION OF PANRETINAL PHOTOCOAGULATION-INDUCED COMPLICATIONS IN PATIENTS WITH SEVERE PROLIFERATIVE DIABETIC RETINOPATHY. <i>Retina</i> , 2008, 28, 1319-1324.	1.0	45
111	Surgical management of retinopathy of prematurity. <i>Current Opinion in Ophthalmology</i> , 2008, 19, 384-390.	1.3	24
112	Effects of Macular Ischemia on the Outcome of Intravitreal Bevacizumab Therapy for Diabetic Macular Edema. <i>Retina</i> , 2008, 28, 957-963.	1.0	108
113	PRIMARY INTRAVITREAL BEVACIZUMAB FOR SUBFOVEAL CHOROIDAL NEOVASCULARIZATION IN AGE-RELATED MACULAR DEGENERATION. <i>Retina</i> , 2008, 28, 1387-1394.	1.0	56
114	Subconjunctival Bevacizumab Injection for Corneal Neovascularization. <i>Cornea</i> , 2008, 27, 142-147.	0.9	127
115	Endoplasmic reticulum stress and diabetic retinopathy. <i>Vascular Health and Risk Management</i> , 0, Volume 4, 115-122.	1.0	27

#	ARTICLE	IF	CITATIONS
116	Update on the Treatment of Diabetic Retinopathy. Scientific World Journal, The, 2008, 8, 98-120.	0.8	32
117	Two Cases of Subconjunctival Bevacizumab Injection to Prevent Bleb Failure After Trabeculectomy. Journal of Korean Ophthalmological Society, 2008, 49, 1345.	0.0	1
118	Bevacizumab-Augmented Retinal Laser Photocoagulation in Proliferative Diabetic Retinopathy: A Randomized Double-Masked Clinical Trial. European Journal of Ophthalmology, 2008, 18, 263-269.	0.7	116
119	Intravitreal Bevacizumab versus Combined Bevacizumab-Triamcinolone versus Macular Laser Photocoagulation in Diabetic Macular Edema. European Journal of Ophthalmology, 2008, 18, 941-948.	0.7	91
120	An Unusual Optic Disc Neovascularization in a Case of Intermediate Uveitis Associated with Multiple Sclerosis. European Journal of Ophthalmology, 2008, 18, 1020-1022.	0.7	7
121	Results of Intravitreal Bevacizumab for Macular Edema with Retinal Vein Occlusion and Diabetic Macular Edema. Journal of Korean Ophthalmological Society, 2008, 49, 1275.	0.0	6
122	Intravitreal Bevacizumab Injection as Preoperative Adjuvant of Vitrectomy for Proliferative Diabetic Retinopathy. Journal of Korean Ophthalmological Society, 2009, 50, 731.	0.0	1
123	Effect of Bevacizumab on Survival and Production of Nitric Oxide in Trabecular Meshwork Cells. Journal of Korean Ophthalmological Society, 2009, 50, 1404.	0.0	5
126	The Efficacy of Intravitreal Bevacizumab in the Treatment of Macular Edema. Journal of Korean Ophthalmological Society, 2009, 50, 1232.	0.0	0
127	Can an Intraoperative Bevacizumab Injection Prevent Recurrent Postvitrectomy Diabetic Vitreous Hemorrhage?. European Journal of Ophthalmology, 2009, 19, 618-621.	0.7	31
128	Intravitreal bevacizumab as an adjunctive therapy before diabetic vitrectomy. Clinical Ophthalmology, 0, , 709.	0.9	15
129	Anti-angiogenic Drugs as an Adjunctive Therapy in the Surgical Treatment of Diabetic Retinopathy. Current Diabetes Reviews, 2009, 5, 52-56.	0.6	16
130	Pegaptanib Sodium versus Pegaptanib Sodium Combined with Macular Laser Photocoagulation or Laser Alone for Diabetic Macular Edema. Journal of Ophthalmology, 2009, 2009, 1-6.	0.6	6
132	Intravitreal Bevacizumab for Treatment of Diabetic Macular Edema. Korean Journal of Ophthalmology: KJO, 2009, 23, 17.	0.5	24
133	Intravitreal Bevacizumab for Diabetic Retinopathy. Current Diabetes Reviews, 2009, 5, 39-46.	0.6	58
134	Effect of Intravitreal Bevacizumab (Avastin) on the Growing Rabbit Eye. Current Eye Research, 2009, 34, 660-665.	0.7	7
135	rAAV.sFlt-1 Gene Therapy Achieves Lasting Reversal of Retinal Neovascularization in the Absence of a Strong Immune Response to the Viral Vector. , 2009, 50, 4279.		43
136	Pharmacotherapy for diabetic retinopathy. Expert Opinion on Pharmacotherapy, 2009, 10, 1123-1131.	0.9	11

#	ARTICLE	IF	CITATIONS
137	Implications of bevacizumab on vascular endothelial growth factor and endostatin in human choroidal neovascularisation. <i>British Journal of Ophthalmology</i> , 2009, 93, 159-165.	2.1	7
138	Treatment of retinal diseases with VEGF antagonists. <i>Progress in Brain Research</i> , 2009, 175, 253-267.	0.9	43
139	Simultaneous Intravitreal and Intracameral Injection of Bevacizumab (Avastin) in Neovascular Glaucoma. <i>Journal of Ocular Pharmacology and Therapeutics</i> , 2009, 25, 259-264.	0.6	12
140	Antiangiogenic therapy with anti-vascular endothelial growth factor modalities for diabetic macular oedema. , 2009, , CD007419.		61
141	Intravitreal bevacizumab (avastin) as an adjuvant treatment in cases of neovascular glaucoma. <i>Middle East African Journal of Ophthalmology</i> , 2009, 16, 75.	0.5	11
142	The Boston Ocular Surface Prosthesis as a Novel Drug Delivery System for Bevacizumab. <i>Seminars in Ophthalmology</i> , 2009, 24, 149-155.	0.8	31
143	Review of Anti-VEGF Therapy in Proliferative Diabetic Retinopathy. <i>Seminars in Ophthalmology</i> , 2009, 24, 87-92.	0.8	82
144	Intravitreal Bevacizumab (Avastin) for the Treatment of Cystoid Macular Edema in Behçet Disease. <i>Ocular Immunology and Inflammation</i> , 2009, 17, 59-64.	1.0	32
145	Bevacizumab (Avastin) in Ocular Processes Other Than Choroidal Neovascularization. <i>Ocular Immunology and Inflammation</i> , 2009, 17, 109-117.	1.0	5
146	Cysteine-rich 61, a Member of the CCN Family, as a Factor Involved in the Pathogenesis of Proliferative Diabetic Retinopathy. , 2009, 50, 3447.		35
147	Inhibitory effects of bevacizumab on angiogenesis and corneal neovascularization. <i>Graefe's Archive for Clinical and Experimental Ophthalmology</i> , 2009, 247, 541-548.	1.0	36
148	Comparison of two doses of primary intravitreal bevacizumab (Avastin) for diffuse diabetic macular edema: results from the Pan-American Collaborative Retina Study Group (PACORES) at 12-month follow-up. <i>Graefe's Archive for Clinical and Experimental Ophthalmology</i> , 2009, 247, 735-743.	1.0	83
149	Suppression of retinal neovascularization by the iNOS inhibitor aminoguanidine in mice of oxygen-induced retinopathy. <i>Graefe's Archive for Clinical and Experimental Ophthalmology</i> , 2009, 247, 919-927.	1.0	26
150	A multimodal approach to eye melanoma: patterns of care and related complications. <i>Oncology Reviews</i> , 2009, 3, 41-49.	0.8	0
151	Intravitreal bevacizumab (avastin) for proliferative diabetic retinopathy: 6-months follow-up. <i>Eye</i> , 2009, 23, 117-123.	1.1	109
152	Management of extensive subfoveal haemorrhage secondary to neovascular age-related macular degeneration. <i>Eye</i> , 2009, 23, 1404-1410.	1.1	54
153	Can a preoperative bevacizumab injection prevent recurrent postvitrectomy diabetic vitreous haemorrhage?. <i>Eye</i> , 2009, 23, 1698-1701.	1.1	45
154	Microvascular lesions of diabetic retinopathy: clues towards understanding pathogenesis?. <i>Eye</i> , 2009, 23, 1496-1508.	1.1	282

#	ARTICLE	IF	CITATIONS
155	The Combination of Intravitreal Bevacizumab and Phacoemulsification Surgery in Patients with Cataract and Coexisting Diabetic Macular Edema. <i>Journal of Ocular Pharmacology and Therapeutics</i> , 2009, 25, 83-90.	0.6	37
156	Bevacizumab (Avastin) for the Treatment of Ocular Disease. <i>Survey of Ophthalmology</i> , 2009, 54, 372-400.	1.7	125
157	Primary Intravitreal Bevacizumab for Diffuse Diabetic Macular Edema. <i>Ophthalmology</i> , 2009, 116, 1488-1497.e1.	2.5	125
158	Intravitreal Bevacizumab for Refractory Pseudophakic Cystoid Macular Edema. <i>Ophthalmology</i> , 2009, 116, 1481-1487.e1.	2.5	90
159	Intravitreal Bevacizumab for Prevention of Early Postvitrectomy Hemorrhage in Diabetic PatientsA Randomized Clinical Trial. <i>Ophthalmology</i> , 2009, 116, 1943-1948.	2.5	144
160	Intravitreal Bevacizumab for Diabetic Macular Edema Associated With Severe Capillary Loss: One-Year Results of a Pilot Study. <i>American Journal of Ophthalmology</i> , 2009, 147, 1022-1030.e5.	1.7	37
161	Pterygia: Pathogenesis and the Role of Subconjunctival Bevacizumab in Treatment. <i>Seminars in Ophthalmology</i> , 2009, 24, 130-134.	0.8	46
162	Retinal Angiography and Optical Coherence Tomography. , 2009, , .		18
163	Effect of Intravitreal Injection of High-Dose Bevacizumab in Monkey Eyes. , 2009, 50, 4905.		38
164	Intravitreal pegaptanib sodium (Macugen[®]) for diabetic macular oedema. <i>Acta Ophthalmologica</i> , 2009, 87, 623-630.	0.6	42
166	Retinopathy of Prematurity. <i>Critical Care Nursing Clinics of North America</i> , 2009, 21, 213-233.	0.4	8
167	THE EFFECT OF UNILATERAL INTRAVITREAL BEVACIZUMAB (AVASTIN), IN THE TREATMENT OF DIFFUSE BILATERAL DIABETIC MACULAR EDEMA. <i>Retina</i> , 2009, 29, 20-26.	1.0	35
168	SHORT-TERM SAFETY AND EFFICACY OF INTRAVITREAL BEVACIZUMAB FOR PSEUDOPHAKIC CYSTOID MACULAR EDEMA. <i>Retina</i> , 2009, 29, 33-37.	1.0	52
169	Intravitreal Bevacizumab for Neovascular Glaucoma. <i>Journal of Glaucoma</i> , 2009, 18, 632-637.	0.8	88
170	SAFETY OF REPEAT INTRAVITREAL INJECTIONS OF BEVACIZUMAB VERSUS RANIBIZUMAB. <i>Retina</i> , 2009, 29, 313-318.	1.0	114
171	VISUAL OUTCOMES AND INCIDENCE OF RECURRENT VITREOUS HEMORRHAGE AFTER VITRECTOMY IN DIABETIC EYES PRETREATED WITH BEVACIZUMAB (AVASTIN). <i>Retina</i> , 2009, 29, 926-931.	1.0	58
172	Anti-VEGF Therapy in Proliferative Diabetic Retinopathy. <i>International Ophthalmology Clinics</i> , 2009, 49, 95-107.	0.3	30
173	PANRETINAL PHOTOCOAGULATION COMBINED WITH INTRAVITREAL BEVACIZUMAB IN HIGH-RISK PROLIFERATIVE DIABETIC RETINOPATHY. <i>Retina</i> , 2009, 29, 516-522.	1.0	80

#	ARTICLE	IF	CITATIONS
174	Intravitreal Injection of Bevacizumab before Vitrectomy for Proliferative Diabetic Retinopathy. <i>European Journal of Ophthalmology</i> , 2009, 19, 848-852.	0.7	77
175	Anti-vascular endothelial growth factor therapy for neovascular ocular diseases other than age-related macular degeneration. <i>Current Opinion in Ophthalmology</i> , 2009, 20, 166-174.	1.3	89
176	SHORT-TERM FLUCTUATION OF DIABETIC MACULAR EDEMA AFTER INTRAVITREAL RANIBIZUMAB INJECTION. <i>Retina</i> , 2009, 29, 1274-1281.	1.0	12
177	INTRAVITREAL BEVACIZUMAB AND PANRETINAL PHOTOCOAGULATION FOR PROLIFERATIVE DIABETIC RETINOPATHY ASSOCIATED WITH VITREOUS HEMORRHAGE. <i>Retina</i> , 2009, 29, 1134-1140.	1.0	52
178	Optical Coherence Tomography for Complete Management of Patients with Diabetic Retinopathy. <i>Current Diabetes Reviews</i> , 2010, 6, 207-214.	0.6	7
179	FIBROUS MEMBRANES IN DIABETIC RETINOPATHY AND BEVACIZUMAB. <i>Retina</i> , 2010, 30, 1012-1016.	1.0	13
180	The Effect of Subconjunctival Suramin on Corneal Neovascularization in Rabbits. <i>Cornea</i> , 2010, 29, 86-92.	0.9	25
181	HISTOLOGY OF FIBROVASCULAR MEMBRANES OF PROLIFERATIVE DIABETIC RETINOPATHY AFTER INTRAVITREAL INJECTION OF BEVACIZUMAB. <i>Retina</i> , 2010, 30, 468-472.	1.0	20
182	THE RESULTS OF INTRAVITREAL BEVACIZUMAB INJECTIONS FOR PERSISTENT NEOVASCULARIZATIONS IN PROLIFERATIVE DIABETIC RETINOPATHY AFTER PHOTOCOAGULATION THERAPY. <i>Retina</i> , 2010, 30, 570-577.	1.0	26
183	DOSE OF INTRAVITREAL BEVACIZUMAB (AVASTIN) USED AS PREOPERATIVE ADJUNCT THERAPY FOR PROLIFERATIVE DIABETIC RETINOPATHY. <i>Retina</i> , 2010, 30, 761-764.	1.0	40
184	INTRAVITREAL BEVACIZUMAB AND/OR MACULAR PHOTOCOAGULATION AS A PRIMARY TREATMENT FOR DIFFUSE DIABETIC MACULAR EDEMA. <i>Retina</i> , 2010, 30, 1638-1645.	1.0	57
185	Perilimbal Bevacizumab Injection for Interface Neovascularization After Deep Anterior Lamellar Keratoplasty. <i>Cornea</i> , 2010, 29, 1268-1272.	0.9	14
187	The effects of intravitreally injected bevacizumab on the retina and retina pigment epithelium: experimental in-vivo electron microscopic study in intact versus vitrectomized eyes. <i>Open Medicine (Poland)</i> , 2010, 5, 745-751.	0.6	1
188	Effect of multiple injections of small divided doses vs single injection of intravitreal bevacizumab on retinal neovascular model in rabbits. <i>Graefe's Archive for Clinical and Experimental Ophthalmology</i> , 2010, 248, 457-466.	1.0	9
189	Intravitreal bevacizumab for surgical treatment of severe proliferative diabetic retinopathy. <i>Graefe's Archive for Clinical and Experimental Ophthalmology</i> , 2010, 248, 785-791.	1.0	96
190	Effect of intravitreal bevacizumab on iris vessels in neovascular glaucoma patients. <i>Graefe's Archive for Clinical and Experimental Ophthalmology</i> , 2010, 248, 1601-1609.	1.0	31
191	Intravitreal bevacizumab in combination with laser therapy for the treatment of severe retinopathy of prematurity (ROP) associated with vitreous or retinal hemorrhage. <i>Graefe's Archive for Clinical and Experimental Ophthalmology</i> , 2010, 248, 1713-1718.	1.0	52
192	Inhibitory effect of PPAR α agonist on the proliferation of human pterygium fibroblasts. <i>Journal of Huazhong University of Science and Technology [Medical Sciences]</i> , 2010, 30, 809-814.	1.0	1

#	ARTICLE	IF	CITATIONS
193	Intravitreal bevacizumab for persistent macular edema with proliferative diabetic retinopathy. <i>International Ophthalmology</i> , 2010, 30, 697-702.	0.6	12
194	Protein delivery for retinal diseases: From basic considerations to clinical applications. <i>Progress in Retinal and Eye Research</i> , 2010, 29, 443-465.	7.3	83
195	Effect of an intravitreal injection of bevacizumab on the expression of VEGF and CD34 in the retina of diabetic rats. <i>Clinical and Experimental Ophthalmology</i> , 2010, 38, 875-884.	1.3	15
196	Use of pegaptanib for recurrent and non-clearing vitreous haemorrhage in proliferative diabetic retinopathy. <i>Eye</i> , 2010, 24, 1315-1319.	1.1	21
197	Long-term Effect of Panretinal Photocoagulation Combined With Intravitreal Bevacizumab in High-risk Proliferative Diabetic Retinopathy. <i>Journal of Korean Ophthalmological Society</i> , 2010, 51, 842.	0.0	1
198	Use of anti-vascular endothelial growth factor for diabetic macular edema. <i>Clinical Ophthalmology</i> , 2010, 4, 493.	0.9	22
199	Comparison of Intravitreal Triamcinolone Versus Bevacizumab in Bilateral Diabetic Macular Edema by Optical Coherence Tomography (OCT) Patterns. <i>Journal of Korean Ophthalmological Society</i> , 2010, 51, 210.	0.0	3
200	Long-Term Tolerability and Serum Concentration of Bevacizumab (Avastin) when Injected in Newborn Rabbit Eyes. , 2010, 51, 3701.		34
202	The Short-Term Efficacy of Intravitreal Ranibizumab in the Treatment of Diabetic Macular Edema. <i>Journal of Korean Ophthalmological Society</i> , 2010, 51, 1453.	0.0	0
203	Thiazolidinediones Reduce Pathological Neovascularization in Ischemic Retina Via an Adiponectin-Dependent Mechanism. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2010, 30, 46-53.	1.1	48
204	Increased Vitreous Shedding of Microparticles in Proliferative Diabetic Retinopathy Stimulates Endothelial Proliferation. <i>Diabetes</i> , 2010, 59, 694-701.	0.3	65
205	Intravitreal Bevacizumab for Diffuse Diabetic Macular Edema: Early Results. <i>Türk Oftalmoloji Dergisi</i> , 2010, 40, 145-150.	0.4	0
206	Intravitreal triamcinolone and bevacizumab as adjunctive treatments to panretinal photocoagulation in diabetic retinopathy. <i>British Journal of Ophthalmology</i> , 2010, 94, 858-863.	2.1	26
207	Applications of Nanobiotechnology in Ophthalmology – Part I. <i>Ophthalmic Research</i> , 2010, 44, 1-16.	1.0	9
208	Intravitreal Bevacizumab for Subfoveal Choroidal Neovascularization in Age-Related Macular Degeneration at Twenty-four Months: The Pan-American Collaborative Retina Study. <i>Ophthalmology</i> , 2010, 117, 1974-1981.e1.	2.5	34
209	Intravitreal bevacizumab for posterior capsule neovascularization. <i>Saudi Journal of Ophthalmology</i> , 2010, 24, 63-65.	0.3	1
210	Current concepts in intravitreal drug therapy for diabetic retinopathy. <i>Saudi Journal of Ophthalmology</i> , 2010, 24, 143-149.	0.3	6
211	Pharmacokinetics of Bevacizumab and Its Effect on Vascular Endothelial Growth Factor after Intravitreal Injection of Bevacizumab in Macaque Eyes. , 2010, 51, 1606.		114

#	ARTICLE	IF	CITATIONS
212	Multi-Modal Proteomic Analysis of Retinal Protein Expression Alterations in a Rat Model of Diabetic Retinopathy. PLoS ONE, 2011, 6, e16271.	1.1	44
213	Effects and Complications of Bevacizumab Use in Patients with Retinopathy of Prematurity: A Multicenter Study in Taiwan. Ophthalmology, 2011, 118, 176-183.	2.5	141
214	Preoperative Intravitreal Bevacizumab Use as an Adjuvant to Diabetic Vitrectomy: Histopathologic Findings and Clinical Implications. Ophthalmology, 2011, 118, 636-641.	2.5	68
215	The Effect of Adjunctive Intravitreal Bevacizumab for Preventing Postvitrectomy Hemorrhage in Proliferative Diabetic Retinopathy. Ophthalmology, 2011, 118, 2218-2226.	2.5	90
216	Diabetic retinopathy – An update. Saudi Journal of Ophthalmology, 2011, 25, 99-111.	0.3	58
217	Repeated intravitreal bevacizumab (Avastin [®]) treatment of persistent new vessels in proliferative diabetic retinopathy after complete panretinal photocoagulation. Acta Ophthalmologica, 2011, 89, 76-81.	0.6	36
218	Treatment of proliferative diabetic retinopathy with anti-VEGF agents. Acta Ophthalmologica, 2011, 89, 405-411.	0.6	89
219	Panretinal photocoagulation (PRP) versus PRP plus intravitreal ranibizumab for high-risk proliferative diabetic retinopathy. Acta Ophthalmologica, 2011, 89, e567-e572.	0.6	58
220	Antiangiogenic drugs and advanced proliferative diabetic retinopathy. Arquivos Brasileiros De Oftalmologia, 2011, 74, 143-146.	0.2	7
221	Retro-mode imaging of fibrovascular membrane in proliferative diabetic retinopathy after intravitreal bevacizumab injection. Clinical Ophthalmology, 2011, 5, 897.	0.9	7
222	Effect of 23-gauge Sutureless Vitrectomy & Preoperative Bevacizumab on Results of Diabetic Vitrectomy. Journal of Korean Ophthalmological Society, 2011, 52, 285.	0.0	0
223	Effect of Focal and Grid Pattern PASCAL Photocoagulation Treatment in Diabetic Macular Edema. Journal of Korean Ophthalmological Society, 2011, 52, 197.	0.0	0
224	Comparison of the Effects Between Bevacizumab and Mitomycin C on the Survival of Fibroblasts. Journal of Korean Ophthalmological Society, 2011, 52, 345.	0.0	3
225	Intravitreal Bevacizumab (Avastin) for Diabetic Retinopathy: The 2010 GLADAOF Lecture. Journal of Ophthalmology, 2011, 2011, 1-13.	0.6	44
226	Prophylactic Intravitreal Bevacizumab for Diabetic Macular Edema (thickening) after Cataract Surgery: Prospective Randomized Study. European Journal of Ophthalmology, 2011, 21, 276-281.	0.7	32
227	Assessment of Anterior Chamber Inflammation after Intravitreal Bevacizumab Injection in Different Ocular Exudative Diseases. European Journal of Ophthalmology, 2011, 21, 156-161.	0.7	11
228	Diagnostic and Therapeutic Challenges. Retina, 2011, 31, 994-997.	1.0	0
229	Combined Intravitreal Bevacizumab and Trabeculectomy With Mitomycin C Versus Trabeculectomy With Mitomycin C Alone for Neovascular Glaucoma. Journal of Glaucoma, 2011, 20, 196-201.	0.8	64

#	ARTICLE	IF	CITATIONS
230	TREATMENT OF MACULAR EDEMA BECAUSE OF OCCLUSIVE VASCULITIS WITH BEVACIZUMAB (AVASTIN). <i>Retina</i> , 2011, 31, 1863-1870.	1.0	5
231	PREOPERATIVE INJECTION OF INTRAVITREAL BEVACIZUMAB IN DENSE DIABETIC VITREOUS HEMORRHAGE. <i>Retina</i> , 2011, 31, 1254-1260.	1.0	43
232	Intravitreal bevacizumab in retinopathy of prematurity: an interventional case series. <i>Graefe's Archive for Clinical and Experimental Ophthalmology</i> , 2011, 249, 1295-1301.	1.0	14
233	Negative correlation between aqueous vascular endothelial growth factor levels and axial length. <i>Japanese Journal of Ophthalmology</i> , 2011, 55, 401-404.	0.9	35
235	Bevacizumab (Avastin) as an Adjunct to Vitrectomy in the Management of Severe Proliferative Diabetic Retinopathy: A Prospective Case Series. <i>Ophthalmic Research</i> , 2011, 45, 23-30.	1.0	14
236	Panretinal Photocoagulation for Proliferative Diabetic Retinopathy. <i>New England Journal of Medicine</i> , 2011, 365, 1520-1526.	13.9	109
237	A systematic review and meta-analysis of clinical outcomes of vitrectomy with or without intravitreal bevacizumab pretreatment for severe diabetic retinopathy. <i>British Journal of Ophthalmology</i> , 2011, 95, 1216-1222.	2.1	81
238	Vascular damage of retina in diabetic retinopathy and its treatment. <i>Expert Review of Ophthalmology</i> , 2012, 7, 73-86.	0.3	0
239	Angioedema after intravitreal bevacizumab injection. <i>Cutaneous and Ocular Toxicology</i> , 2012, 31, 85-86.	0.5	6
240	Connection of pericyte-angiopoietin-Tie-2 system in diabetic retinopathy: friend or foe?. <i>Future Medicinal Chemistry</i> , 2012, 4, 2163-2176.	1.1	11
241	Bevacizumab and ranibizumab tachyphylaxis in the treatment of choroidal neovascularisation. <i>British Journal of Ophthalmology</i> , 2012, 96, 14-20.	2.1	159
242	Effect of Vitrectomy on Aqueous VEGF Concentration and Pharmacokinetics of Bevacizumab in Macaque Monkeys. , 2012, 53, 5877.		86
243	Ocular Blood Flow in Diabetes: Contribution to the Microvascular Lesions of Diabetic Retinopathy. , 2012, , 365-387.		0
244	Triamcinolone and Bevacizumab as Adjunctive Therapies to Panretinal Photocoagulation for Proliferative Diabetic Retinopathy. <i>ISRN Ophthalmology</i> , 2012, 2012, 1-10.	1.7	7
245	The Role of Angiogenesis in the Development of Proliferative Diabetic Retinopathy: Impact of Intravitreal Anti-VEGF Treatment. <i>Experimental Diabetes Research</i> , 2012, 2012, 1-8.	3.8	74
246	Topical and Subconjunctival Bevacizumab for Corneal Neovascularization in an Experimental Rat Model. <i>Ophthalmic Research</i> , 2012, 48, 118-123.	1.0	23
247	Clinical and Electrophysiologic Outcome in Patients with Neovascular Glaucoma Treated with and without Bevacizumab. <i>European Journal of Ophthalmology</i> , 2012, 22, 563-574.	0.7	28
248	Effects of Subconjunctival Bevacizumab on Corneal Neovascularization. <i>Cornea</i> , 2012, 31, 937-944.	0.9	24

#	ARTICLE	IF	CITATIONS
249	Phacoemulsification with Intravitreal Bevacizumab Injection in Patients with Cataract and Coexisting Diabetic Retinopathy: Prospective Randomized Study. <i>Journal of Ocular Pharmacology and Therapeutics</i> , 2012, 28, 212-218.	0.6	16
250	Vascular endothelial growth factors in retinal and choroidal neovascular diseases. <i>Annals of Medicine</i> , 2012, 44, 1-17.	1.5	46
251	Ranibizumab versus Bevacizumab to Treat Neovascular Age-related Macular Degeneration. <i>Ophthalmology</i> , 2012, 119, 1399-1411.	2.5	724
252	Succinate Increases in the Vitreous Fluid of Patients With Active Proliferative Diabetic Retinopathy. <i>American Journal of Ophthalmology</i> , 2012, 153, 896-902.e1.	1.7	18
253	Diabetic Retinopathy and Age-Related Macular Degeneration in the U.S. <i>American Journal of Preventive Medicine</i> , 2012, 43, 48-54.	1.6	40
254	Antiangiogenic therapy with anti-vascular endothelial growth factor modalities for diabetic macular oedema. , 2012, 12, CD007419.		75
255	Intravitreal bevacizumab increases intraocular interleukin-6 levels at 1day after injection in patients with proliferative diabetic retinopathy. <i>Cytokine</i> , 2012, 60, 535-539.	1.4	26
256	Effects of avastin on expression of AQP4 in MÄ¼ller cells under hypoxia. <i>Journal of Huazhong University of Science and Technology [Medical Sciences]</i> , 2012, 32, 607-612.	1.0	2
257	Inhibitory Activity of Bevacizumab to Differentiation of Retinoblastoma Cells. <i>PLoS ONE</i> , 2012, 7, e33456.	1.1	26
258	Anti-VEGF Agents for Ocular Angiogenesis and Vascular Permeability. <i>Journal of Ophthalmology</i> , 2012, 2012, 1-11.	0.6	43
259	Bevacizumab and Rapamycin Can Decrease Corneal Opacity and Apoptotic Keratocyte Number following Photorefractive Keratectomy. , 2012, 53, 7645.		10
260	In Vitro Effects of Bevacizumab Treatment on Newborn Rat Retinal Cell Proliferation, Death, and Differentiation. , 2012, 53, 7904.		15
261	Six-month visual outcome after pars plana vitrectomy in proliferative diabetic retinopathy with or without a single preoperative injection of intravitreal bevacizumab. <i>International Ophthalmology</i> , 2012, 32, 135-144.	0.6	26
262	Secondary rhegmatogenous retinal detachment following intravitreal bevacizumab in patients with vitreous hemorrhage or tractional retinal detachment secondary to Ealesâ€™ disease. <i>Graefe's Archive for Clinical and Experimental Ophthalmology</i> , 2012, 250, 685-690.	1.0	19
263	The subconjunctival use of cetuximab and bevacizumab in inhibition of corneal angiogenesis. <i>Graefe's Archive for Clinical and Experimental Ophthalmology</i> , 2012, 250, 1161-1167.	1.0	8
264	Ruthenium-106 brachytherapy and intravitreal bevacizumab for retinal capillary hemangioma. <i>International Ophthalmology</i> , 2012, 32, 71-75.	0.6	15
265	The toxicity of intrathecal bevacizumab in a rabbit model of leptomeningeal carcinomatosis. <i>Journal of Neuro-Oncology</i> , 2012, 106, 81-88.	1.4	17
266	Acute bacterial endophthalmitis after intravitreal bevacizumab injection: Case report and literature review. <i>Saudi Journal of Ophthalmology</i> , 2013, 27, 55-57.	0.3	6

#	ARTICLE	IF	CITATIONS
267	Alternative treatments to inhibit VEGF in age-related choroidal neovascularisation: 2-year findings of the IVAN randomised controlled trial. <i>Lancet, The</i> , 2013, 382, 1258-1267.	6.3	623
268	Pharmacology at Surgery. , 2013, , 2094-2102.		0
269	An Updated Study of the Use of Bevacizumab in the Treatment of Patients with Prethreshold Retinopathy of Prematurity in Taiwan. <i>American Journal of Ophthalmology</i> , 2013, 155, 150-158.e1.	1.7	116
270	Randomized Clinical Trial Evaluating Intravitreal Ranibizumab or Saline for Vitreous Hemorrhage From Proliferative Diabetic Retinopathy. <i>JAMA Ophthalmology</i> , 2013, 131, 283.	1.4	90
271	Intravitreal Avastin as an adjunct in patients with proliferative diabetic retinopathy undergoing pars plana vitrectomy. <i>Pakistan Journal of Medical Sciences</i> , 2013, 29, 590-2.	0.3	13
272	Exploratory Analysis of the Effect of Intravitreal Ranibizumab or Triamcinolone on Worsening of Diabetic Retinopathy in a Randomized Clinical Trial. <i>JAMA Ophthalmology</i> , 2013, 131, 1033.	1.4	99
273	Effect of bevacizumab (Avastin TM) on mitochondrial function of in vitro retinal pigment epithelial, neurosensory retinal and microvascular endothelial cells. <i>Indian Journal of Ophthalmology</i> , 2013, 61, 705.	0.5	14
274	Inflammation and Pharmacological Treatment in Diabetic Retinopathy. <i>Mediators of Inflammation</i> , 2013, 2013, 1-8.	1.4	72
275	Inhibition of Corneal Neovascularization with the Combination of Bevacizumab and Plasmid Pigment Epithelium-Derived Factor-Synthetic Amphiphile INTERaction-18 (p-PEDF-SAINT-18) Vector in a Rat Corneal Experimental Angiogenesis Model. <i>International Journal of Molecular Sciences</i> , 2013, 14, 8291-8305.	1.8	8
276	Subconjunctival Injection of Low-Molecular-Weight Heparinâ€“Taurocholate 7 Inhibits Corneal Neovascularization. <i>Cornea</i> , 2013, 32, 1488-1492.	0.9	12
277	Intravitreal Bevacizumab (Avastin) and Panretinal Photocoagulation in the Treatment of High-Risk Proliferative Diabetic Retinopathy. <i>Journal of Ocular Pharmacology and Therapeutics</i> , 2013, 29, 550-555.	0.6	46
278	INTRAVITREAL BEVACIZUMAB IN THE TREATMENT OF DIABETIC OCULAR NEOVASCULARIZATION. <i>Retina</i> , 2013, 33, 748-755.	1.0	15
279	Personalized Medicine in Ophthalmology: From Pharmacogenetic Biomarkers to Therapeutic and Dosage Optimization. <i>Journal of Personalized Medicine</i> , 2013, 3, 40-69.	1.1	23
280	Effects of Diabetic Retinopathy and Intravitreal Bevacizumab Injection on Choroidal Thickness in Diabetic Patients. <i>Journal of Korean Ophthalmological Society</i> , 2013, 54, 1520.	0.0	4
281	Tratamento cirÃºrgico da retinopatia diabÃ©tica. <i>Revista Brasileira De Oftalmologia</i> , 2013, 72, 204-209.	0.1	0
282	Risk Factors for Neovascular Glaucoma after Vitrectomy in Patients with Proliferative Diabetic Retinopathy. <i>Journal of Korean Ophthalmological Society</i> , 2013, 54, 1868.	0.0	2
283	The Change of Microaneurysm in Diabetic Retinopathy Patients Who Undergo Intravitreal Avastin (Bevacizumab) Injection. <i>Journal of Korean Ophthalmological Society</i> , 2014, 55, 1481.	0.0	2
284	Combined Tractional and Rhegmatogenous Retinal Detachment in Proliferative Diabetic Retinopathy in the Anti-VEGF Era. <i>Journal of Ophthalmology</i> , 2014, 2014, 1-11.	0.6	24

#	ARTICLE	IF	CITATIONS
285	Perfluorocarbon in vitreoretinal surgery and preoperative bevacizumab in diabetic tractional retinal detachment. <i>World Journal of Diabetes</i> , 2014, 5, 724.	1.3	5
286	Comparison between Simultaneous Intracameral and Intravitreal Injection and Intravitreal Injection of Bevacizumab in Neovascular Glaucoma. <i>Journal of Korean Ophthalmological Society</i> , 2014, 55, 1039.	0.0	1
287	Intravitreal Anti-VEGF Treatment as Adjunctive Treatment in the Management of Diabetic Retinopathy. <i>Journal of Ocular Pharmacology and Therapeutics</i> , 2014, 30, 303-303.	0.6	0
288	Treatment of macular edema in diabetic retinopathy: comparison of the efficacy of intravitreal bevacizumab and ranibizumab injections. <i>Expert Review of Ophthalmology</i> , 2014, 9, 139-143.	0.3	11
289	Anti-vascular endothelial growth factor for proliferative diabetic retinopathy. <i>The Cochrane Library</i> , 2014, , CD008721.	1.5	43
290	Anterior Retinal Cryotherapy and Intravitreal Injection of Bevacizumab in the Treatment of Nonclearing Vitreous Hemorrhage in Proliferative Diabetic Retinopathy. <i>Journal of Ocular Pharmacology and Therapeutics</i> , 2014, 30, 353-358.	0.6	5
291	Pharmacotherapy for Treatment and Prevention of Proliferative Diabetic Retinopathy. <i>Current Ophthalmology Reports</i> , 2014, 2, 175-183.	0.5	0
292	INTRAVITREAL BEVACIZUMAB FOR POSTOPERATIVE RECURRENT VITREOUS HEMORRHAGE AFTER VITRECTOMY FOR PROLIFERATIVE DIABETIC RETINOPATHY. <i>Retina</i> , 2014, 34, 1177-1181.	1.0	17
293	Bevacizumab Reduces Neurocan Content and Gene Expression in Newborn Rat Retina In Vitro. , 2014, 55, 5109.		6
294	ELEVATED HYDROGEN SULFIDE LEVELS IN VITREOUS BODY AND PLASMA IN PATIENTS WITH PROLIFERATIVE DIABETIC RETINOPATHY. <i>Retina</i> , 2014, 34, 2003-2009.	1.0	21
295	Intravitreal bevacizumab effects on VEGF levels in distant organs: an experimental study. <i>Cutaneous and Ocular Toxicology</i> , 2014, 33, 275-282.	0.5	8
296	İntravitreal Bevacizumab'ın Sağ Solun Retina Hücresinde Apoptozis Üzerine Etkileri. <i>Türk Oftalmoloji Dergisi</i> , 2014, 44, 39-44.	0.4	0
297	Efficacy of Intralesional Bevacizumab Administration in Primary Pterygium. <i>Eye and Contact Lens</i> , 2014, 40, 46-50.	0.8	8
298	Effects of Subconjunctival Tocilizumab Versus Bevacizumab in Treatment of Corneal Neovascularization in Rabbits. <i>Cornea</i> , 2014, 33, 1088-1094.	0.9	16
299	A review of anti-VEGF agents for proliferative diabetic retinopathy. <i>Eye</i> , 2014, 28, 510-520.	1.1	200
300	Current and investigational pharmacotherapeutic approaches for modulating retinal angiogenesis. <i>Expert Review of Clinical Pharmacology</i> , 2014, 7, 375-391.	1.3	21
301	TWEAK/Fn14 Pathway Is a Novel Mediator of Retinal Neovascularization. , 2014, 55, 801.		27
302	Anti-vascular endothelial growth factor for diabetic macular oedema. , 2014, , CD007419.		113

#	ARTICLE	IF	CITATIONS
304	Clinical Strategies in the Management of Diabetic Retinopathy. , 2014, , .		8
305	Advanced Proliferative Diabetic Retinopathy. , 2014, , 163-178.		0
306	The Role of Intraoperative Bevacizumab for Prevention of Postoperative Vitreous Hemorrhage in Diabetic Vitreous Hemorrhage. European Journal of Ophthalmology, 2014, 24, 88-93.	0.7	7
307	EFFECTS OF INTRAVITREAL INJECTION OF BEVACIZUMAB ON INFLAMMATORY CYTOKINES IN THE VITREOUS WITH PROLIFERATIVE DIABETIC RETINOPATHY. Retina, 2014, 34, 165-171.	1.0	24
308	Correspondence. Retina, 2015, 35, e29.	1.0	0
309	Reply. Retina, 2015, 35, e29-e30.	1.0	0
310	New Therapeutic Approaches in Diabetic Retinopathy. Review of Diabetic Studies, 2015, 12, 196-210.	0.5	28
311	The Vitreomacular Interface in Diabetic Retinopathy. Journal of Ophthalmology, 2015, 2015, 1-10.	0.6	11
312	MicroRNA miR-466 inhibits Lymphangiogenesis by targeting prospero-related homeobox 1 in the alkali burn corneal injury model. Journal of Biomedical Science, 2015, 22, 3.	2.6	44
313	Anti-vascular Endothelial Growth Factor With or Without Pneumatic Displacement for Submacular Hemorrhage. American Journal of Ophthalmology, 2015, 159, 904-914.e1.	1.7	39
314	Microarray Analysis of Gene Expression in Fibrovascular Membranes Excised From Patients With Proliferative Diabetic Retinopathy. Investigative Ophthalmology and Visual Science, 2015, 56, 932-946.	3.3	64
315	A new kind of labyrinth-like capillary is responsible for leakage from human choroidal neovascular endothelium, as investigated by high-resolution electron microscopy. Graefes's Archive for Clinical and Experimental Ophthalmology, 2015, 253, 681-689.	1.0	5
316	The role of ranibizumab in the management of diabetic retinopathy. Expert Review of Ophthalmology, 2015, 10, 329-340.	0.3	1
317	Outcomes after Intravitreal Bevacizumab versus Laser Photocoagulation for Retinopathy of Prematurity. Ophthalmology, 2015, 122, 1008-1015.	2.5	179
318	Beneficial Effects of Adjuvant Intravitreal Bevacizumab Injection on Outcomes of Ahmed Glaucoma Valve Implantation in Patients with Neovascular Glaucoma: Systematic Literature Review. Journal of Ocular Pharmacology and Therapeutics, 2015, 31, 198-203.	0.6	36
319	Feasibility of Telemedicine in Detecting Diabetic Retinopathy and Age-Related Macular Degeneration. Seminars in Ophthalmology, 2015, 30, 81-95.	0.8	23
320	Characteristics of Retinal Neovascularization in Proliferative Diabetic Retinopathy Imaged by Optical Coherence Tomography Angiography. , 2016, 57, 6247.		116
321	Treatment of diabetic retinopathy: Recent advances and unresolved challenges. World Journal of Diabetes, 2016, 7, 333.	1.3	114

#	ARTICLE	IF	CITATIONS
322	Neurodevelopmental Outcomes in Infants with Retinopathy of Prematurity and Bevacizumab Treatment. PLoS ONE, 2016, 11, e0148019.	1.1	121
323	Diabetic retinopathy clinical practice guidelines: Customized for Iranian population. Journal of Ophthalmic and Vision Research, 2016, 11, 394.	0.7	10
324	Long-term Outcomes After Preoperative Intravitreal Injection of Bevacizumab Before Trabeculectomy for Neovascular Glaucoma. Journal of Glaucoma, 2016, 25, 281-284.	0.8	15
325	Anti-angiogenic therapy (bevacizumab) in the management of oral lichen planus. European Journal of Oral Sciences, 2016, 124, 119-126.	0.7	9
326	Comment on "Cellular and molecular aspects of diabetic nephropathy; the role of VEGF-A". Nefrologia, 2016, 36, 705.	0.2	0
327	The adjunctive use of pre-operative intravitreal bevacizumab in the setting of proliferative diabetic retinopathy. Saudi Journal of Ophthalmology, 2016, 30, 217-220.	0.3	6
328	Effect of Intravitreal Anti-VEGF Therapy on the Severity of Diabetic Retinopathy. Current Ophthalmology Reports, 2016, 4, 61-70.	0.5	2
329	Bevacizumab clearance through the iridocorneal angle following intravitreal injection in a rat model. Experimental Eye Research, 2016, 145, 412-416.	1.2	14
330	Cost Evaluation of Panretinal Photocoagulation versus Intravitreal Ranibizumab for Proliferative Diabetic Retinopathy. Ophthalmology, 2016, 123, 1912-1918.	2.5	44
331	Comment on "Cellular and molecular aspects of diabetic nephropathy; the role of VEGF-A". Nefrologia, 2016, 36, 705.	0.2	0
332	Vascular Endothelial Growth Factor Inhibitors for Diabetic Retinopathy. Current Diabetes Reports, 2016, 16, 122.	1.7	24
333	An Update in the Management of Proliferative Diabetic Retinopathy. International Ophthalmology Clinics, 2016, 56, 209-225.	0.3	3
334	Effects of Combined Photodynamic Therapy and Topical Bevacizumab Treatment on Corneal Neovascularization in Rabbits. Cornea, 2016, 35, 1615-1620.	0.9	14
335	INTRAVITREAL CONBERCEPT (KH902) FOR SURGICAL TREATMENT OF SEVERE PROLIFERATIVE DIABETIC RETINOPATHY. Retina, 2016, 36, 938-943.	1.0	63
337	Submacular hemorrhage in neovascular age-related macular degeneration: A synthesis of the literature. Survey of Ophthalmology, 2016, 61, 18-32.	1.7	102
338	Intravitreal Bevacizumab for the Treatment of Vitreous Hemorrhage Due to Proliferative Diabetic Retinopathy. American Journal of Ophthalmology, 2017, 176, 194-202.	1.7	28
339	Neovascular glaucoma after vitrectomy in patients with proliferative diabetic retinopathy. Medicine (United States), 2017, 96, e6263.	0.4	25
340	Cellular stress response in human Müller cells (MIO-M1) after bevacizumab treatment. Experimental Eye Research, 2017, 160, 1-10.	1.2	8

#	ARTICLE	IF	CITATIONS
341	Targeting Vascular Endothelial Growth Factor. , 2017, , 99-139.		0
342	INTRAVITREAL BEVACIZUMAB FOR PROLIFERATIVE DIABETIC RETINOPATHY. <i>Retina</i> , 2017, 37, 334-343.	1.0	43
343	Genetic analysis and clinical features of X-linked retinoschisis in Chinese patients. <i>Scientific Reports</i> , 2017, 7, 44060.	1.6	16
345	A positive circuit of VEGF increases Glut-1 expression by increasing HIF-1 α gene expression in human retinal endothelial cells. <i>Archives of Pharmacal Research</i> , 2017, 40, 1433-1442.	2.7	13
346	The Role of Perioperative Anti-VEGF During Vitrectomy for Vitreous Hemorrhage in Relation to Postoperative Nonclearing Vitreous Hemorrhage and Cystoid Macular Edema. <i>Journal of Vitreoretinal Diseases</i> , 2017, 1, 379-384.	0.2	2
347	Preoperative Bevacizumab Administration in Proliferative Diabetic Retinopathy Patients Undergoing Vitrectomy: A Randomized and Controlled Trial Comparing Interval Variation. <i>American Journal of Ophthalmology</i> , 2017, 183, 1-10.	1.7	42
348	A Novel Peptide Derived From Tissue α 2 Type Plasminogen Activator Potently Inhibits Angiogenesis and Corneal Neovascularization. <i>Journal of Cellular Biochemistry</i> , 2017, 118, 1132-1143.	1.2	6
349	The Impact of Switching Anti-Vascular Endothelial Growth Factor Therapy in the Management of Exudative Age-Related Macular Degeneration. <i>Ophthalmic Surgery Lasers and Imaging Retina</i> , 2017, 48, 859-869.	0.4	2
350	Treatment of Tongue Lymphangioma with Intralesional Combination Injection of Steroid, Bleomycin and Bevacizumab. <i>Archives of Craniofacial Surgery</i> , 2017, 18, 54-58.	0.4	10
351	The Choroid in Retinal Vascular Diseases. , 2017, , 289-305.		1
352	Ranibizumab Plus Panretinal Photocoagulation versus Panretinal Photocoagulation Alone for High-Risk Proliferative Diabetic Retinopathy (PROTEUS Study). <i>Ophthalmology</i> , 2018, 125, 691-700.	2.5	84
353	BIMANUAL MICROINCISION VITREOUS SURGERY FOR SEVERE PROLIFERATIVE DIABETIC RETINOPATHY. <i>Retina</i> , 2018, 38, S134-S145.	1.0	18
354	Cost Evaluation of Early Vitrectomy versus Panretinal Photocoagulation and Intravitreal Ranibizumab for Proliferative Diabetic Retinopathy. <i>Ophthalmology</i> , 2018, 125, 1393-1400.	2.5	31
355	EFFICACY OF INTRAVITREAL RANIBIZUMAB INJECTIONS IN THE TREATMENT OF VITREOUS HEMORRHAGE RELATED TO PROLIFERATIVE DIABETIC RETINOPATHY. <i>Retina</i> , 2018, 38, 1127-1133.	1.0	28
356	SHORT-TERM OUTCOMES AFTER INTRAVITREAL INJECTIONS OF CONBERCEPT VERSUS RANIBIZUMAB FOR THE TREATMENT OF RETINOPATHY OF PREMATURITY. <i>Retina</i> , 2018, 38, 1595-1604.	1.0	32
357	The inflammasome pathway is amplified and perpetuated in an autocrine manner through connexin43 hemichannel mediated ATP release. <i>Biochimica Et Biophysica Acta - General Subjects</i> , 2018, 1862, 385-393.	1.1	87
358	Editorial on photoreceptor glucose metabolism determines normal retinal vascular growth. <i>Annals of Eye Science</i> , 2018, 3, 14-14.	1.1	0
359	The Effect of Avastin on Posterior Capsular Opacification after Phacoemulsification: A Randomized Controlled Trial Mitsugu. <i>Journal of Clinical Trials</i> , 2018, 08, ,	0.1	0

#	ARTICLE	IF	CITATIONS
360	Timing of neovascular regression in eyes with high-risk proliferative diabetic retinopathy without macular edema treated initially with intravitreal bevacizumab. <i>Clinical Ophthalmology</i> , 2019, Volume 13, 27-31.	0.9	10
361	Bevacizumab before Diabetic Vitrectomy. <i>Ophthalmology Retina</i> , 2018, 2, 1010-1020.	1.2	10
362	Intravitreal Bevacizumab Injection Attenuates Diabetic Retinopathy in Adult Rats with Experimentally Induced Diabetes in the Early Stage. <i>Journal of Diabetes Research</i> , 2018, 2018, 1-18.	1.0	9
363	Role of oxidative stress, inflammation, hypoxia and angiogenesis in the development of diabetic retinopathy. <i>Saudi Journal of Ophthalmology</i> , 2018, 32, 318-323.	0.3	93
364	Diabetes and the Eye. <i>Endocrinology</i> , 2018, , 1-44.	0.1	0
365	<p>Effect Of Bevacizumab On Growth Of Human Nasal Polyposis In Vitro; An Off-Label Use Of Anti-Angiogenic Agent For Nasal Polyposis Treatment</p>. <i>Drug Design, Development and Therapy</i> , 2019, Volume 13, 3383-3389.	2.0	2
366	In vivo monitoring the dynamic process of acute retinal hemorrhage and repair in zebrafish with spectral-domain optical coherence tomography. <i>Journal of Biophotonics</i> , 2019, 12, e201900235.	1.1	10
367	Reoperation following vitrectomy for diabetic vitreous hemorrhage with versus without preoperative intravitreal bevacizumab. <i>BMC Ophthalmology</i> , 2019, 19, 200.	0.6	7
368	Single-Dose Intravitreal Conbercept before Panretinal Photocoagulation as an Effective Adjunctive Treatment in Chinese Proliferative Diabetic Retinopathy. <i>Ophthalmologica</i> , 2019, 242, 59-68.	1.0	6
369	Preoperative Bevacizumab for Tractional Retinal Detachment in Proliferative Diabetic Retinopathy: A Prospective Randomized Clinical Trial. <i>American Journal of Ophthalmology</i> , 2019, 207, 279-287.	1.7	33
370	Influence of Baseline Macular Edema on Cost Evaluation of Panretinal Photocoagulation vs Intravitreal Ranibizumab for Proliferative Diabetic Retinopathy. <i>Journal of Vitreoretinal Diseases</i> , 2019, 3, 346-353.	0.2	0
371	Incidence and Risk Factors for Tractional Macular Detachment after Anti-Vascular Endothelial Growth Factor Agent Pretreatment before Vitrectomy for Complicated Proliferative Diabetic Retinopathy. <i>Journal of Clinical Medicine</i> , 2019, 8, 1960.	1.0	11
373	Sequence effect in the treatment of proliferative diabetic retinopathy with intravitreal ranibizumab and panretinal photocoagulation. <i>European Journal of Ophthalmology</i> , 2020, 30, 34-39.	0.7	5
374	Intravitreal ranibizumab for persistent diabetic vitreous haemorrhage: a randomised, double-masked, placebo-controlled feasibility study.. <i>Acta Ophthalmologica</i> , 2020, 98, e960-e967.	0.6	1
375	Management of a Submacular Hemorrhage Secondary to Age-Related Macular Degeneration: A Comparison of Three Treatment Modalities. <i>Journal of Clinical Medicine</i> , 2020, 9, 3088.	1.0	9
376	Causes and Clinical Impact of Loss to Follow-Up in Patients with Proliferative Diabetic Retinopathy. <i>Journal of Ophthalmology</i> , 2020, 2020, 1-8.	0.6	16
377	Comparison of outcomes of four different treatment modalities for diabetic vitreous haemorrhage. <i>Scientific Reports</i> , 2020, 10, 3674.	1.6	5
378	<p>The Role of Head Elevation in Treatment of Vitreous Haemorrhage</p>. <i>Clinical Ophthalmology</i> , 2020, Volume 14, 7-13.	0.9	0

#	ARTICLE	IF	CITATIONS
379	Intravitreal Aflibercept injection with Panretinal photocoagulation versus early Vitrectomy for diabetic vitreous hemorrhage: randomized clinical trial. <i>BMC Ophthalmology</i> , 2020, 20, 130.	0.6	7
380	Eales's Disease. , 2021, , 1-13.		0
381	Efficacy of bevacizumab for vitreous haemorrhage in proliferative diabetic retinopathy with prior complete panretinal photocoagulation. <i>Eye</i> , 2021, 35, 3056-3063.	1.1	5
382	Cytokines associated with hemorrhage in proliferative diabetic retinopathy. <i>International Ophthalmology</i> , 2021, 41, 1845-1853.	0.6	5
383	Bevacizumab for diabetic macular oedema: one-year treatment outcomes from the Fight Retinal Blindness! Registry. <i>Eye</i> , 2021, , .	1.1	4
384	Intravitreal bevacizumab (IVB) versus IVB in combination with pars plana vitrectomy for vitreous hemorrhage secondary to proliferative diabetic retinopathy: a randomized clinical trial. <i>International Journal of Retina and Vitreous</i> , 2021, 7, 35.	0.9	4
385	Recent trends in drug-delivery systems for the treatment of diabetic retinopathy and associated fibrosis. <i>Advanced Drug Delivery Reviews</i> , 2021, 173, 439-460.	6.6	25
386	Aflibercept clearance through the drainage system in a rat model. <i>International Journal of Retina and Vitreous</i> , 2021, 7, 53.	0.9	4
387	Cataract Surgery and Diabetic Retinopathy. , 2010, , 305-323.		3
388	Treatment of Proliferative Diabetic Retinopathy. , 2010, , 227-304.		4
389	Ranibizumab in choroidal neovascularisation associated with ocular sarcoidosis. <i>BMJ Case Reports</i> , 2013, 2013, bcr2013010288-bcr2013010288.	0.2	3
390	Intravitreal anti-inflammatory treatment for uveitis. <i>British Journal of Ophthalmology</i> , 2007, 91, 135-136.	2.1	5
391	Intravitreal ziv-aflibercept in diabetic vitreous hemorrhage. <i>International Journal of Retina and Vitreous</i> , 2020, 6, 2.	0.9	3
392	The Angio-Fibrotic Switch of VEGF and CTGF in Proliferative Diabetic Retinopathy. <i>PLoS ONE</i> , 2008, 3, e2675.	1.1	197
393	Inhibition of Oxygen-Induced Ischemic Retinal Neovascularization with Adenoviral 15-Lipoxygenase-1 Gene Transfer via Up-Regulation of PPAR- β and Down-Regulation of VEGFR-2 Expression. <i>PLoS ONE</i> , 2014, 9, e85824.	1.1	14
394	Ranibizumab in neovascular age-related macular degeneration. <i>Clinical Interventions in Aging</i> , 2006, 1, 451-466.	1.3	15
395	Endoplasmic reticulum stress and diabetic retinopathy. <i>Vascular Health and Risk Management</i> , 2008, 4, 115-122.	1.0	66
396	Efficacy of intravitreal bevacizumab (Avastin TM) for short-term treatment of diabetic macular edema. <i>Journal of Medical Investigation</i> , 2009, 56, 111-115.	0.2	8

#	ARTICLE	IF	CITATIONS
397	Diabetic Retinopathy: Understanding Pathologic Angiogenesis and Exploring its Treatment Options. The Open Circulation & Vascular Journal, 2012, 3, 30-42.	0.4	5
398	Role of chronic inflammation in diabetic retinopathy. Inflammation and Regeneration, 2013, 33, 230-237.	1.5	2
399	Outcome of a Single Intravitreal Bevacizumab Injection on the Visual Acuity and Course of Pars Plana Vitrectomy in Proliferative Diabetic Retinopathy. Current Eye Research, 2013, , 1-6.	0.7	2
400	Intravitreal Bevacizumab for Macular Edema From Idiopathic Juxtafoveal Retinal Telangiectasis. Ophthalmic Surgery Lasers and Imaging Retina, 2007, 38, 164-166.	0.4	30
401	Intravitreal Bevacizumab in Aggressive Posterior Retinopathy of Prematurity. Ophthalmic Surgery Lasers and Imaging Retina, 2007, 38, 233-237.	0.4	132
402	Comparative Study of Analgesic Effectiveness Using Three Different Anesthetic Techniques for Intravitreal Injection of Bevacizumab. Ophthalmic Surgery Lasers and Imaging Retina, 2009, 40, 13-18.	0.4	39
403	Ghost Cell Glaucoma After Intravitreal Bevacizumab for Postoperative Vitreous Hemorrhage Following Vitrectomy for Proliferative Diabetic Retinopathy. Ophthalmic Surgery Lasers and Imaging Retina, 2010, 41, 72-77.	0.4	10
404	The Relation Between Bevacizumab Injection and the Formation of Subretinal Fibrosis in Diabetic Patients With Panretinal Photocoagulation. Ophthalmic Surgery Lasers and Imaging Retina, 2010, 41, 190-195.	0.4	17
405	Computer-Assisted Image Processing for a Simulated Stereo Effect of Ocular Fundus and Fluorescein Angiography Photographs. Ophthalmic Surgery Lasers and Imaging Retina, 2010, 41, 293-300.	0.4	2
406	Adenoviral 15-lipoxygenase-1 gene transfer inhibits hypoxia-induced proliferation of retinal microvascular endothelial cells in vitro. International Journal of Ophthalmology, 2012, 5, 562-9.	0.5	6
407	Short term apoptotic activity of intravitreal bevacizumab on rabbit retina. International Journal of Ophthalmology, 2013, 6, 785-9.	0.5	2
408	Comparison of the effect of intravitreal bevacizumab and intravitreal fasudil on retinal VEGF, TNF α , and caspase 3 levels in an experimental diabetes model. International Journal of Ophthalmology, 2014, 7, 57-61.	0.5	4
409	Role of Carbon Monoxide in Neurovascular Repair Processing. Biomolecules and Therapeutics, 2018, 26, 93-100.	1.1	26
410	Bevacizumab: Off-label use in ophthalmology. Indian Journal of Ophthalmology, 2007, 55, 417.	0.5	58
411	Intravitreal bevacizumab (Avastin) treatment of diffuse diabetic macular edema in an Indian population. Indian Journal of Ophthalmology, 2007, 55, 451.	0.5	37
412	Intracameral injection of bevacizumab (Avastin) to treat anterior chamber neovascular membrane in a painful blind eye. Indian Journal of Ophthalmology, 2007, 55, 460.	0.5	15
413	Lenz microphthalmic syndrome in an Indian patient. Indian Journal of Ophthalmology, 2007, 55, 462.	0.5	5
414	A proposed new classification for diabetic retinopathy: The concept of primary and secondary vitreopathy. Indian Journal of Ophthalmology, 2008, 56, 23.	0.5	9

#	ARTICLE	IF	CITATIONS
415	Characteristics of macular edema in behcet disease after intravitreal bevacizumab injection. Journal of Ophthalmic and Vision Research, 2017, 12, 44.	0.7	6
417	The role of anti-vascular endothelial growth factor (anti-VEGF) in the management of proliferative diabetic retinopathy. Drugs in Context, 2018, 7, 1-10.	1.0	108
418	Suprachoroidal delivery of bevacizumab in rabbit in vivo eyes: Rapid distribution throughout the posterior segment. European Journal of Pharmaceutics and Biopharmaceutics, 2021, 169, 200-210.	2.0	5
419	Neuroglial Dysfunction in Diabetic Retinopathy. , 2008, , 283-301.		1
420	Anti-VEGF Therapy as an Emerging Treatment for Diabetic Retinopathy. , 2008, , 401-422.		0
421	Diabetic Macular Edema. , 2008, , 1793-1806.		4
422	Diagnosis, Management, and Treatment of Nonproliferative Diabetic Retinopathy. , 2008, , 1775-1791.		1
424	Effectiveness of Preoperative Intravitreal Bevacizumab Injections in Pars Plana Vitrectomy for Proliferative Diabetic Retinopathy. Journal of Korean Ophthalmological Society, 2009, 50, 1221.	0.0	1
430	INTRAVITREAL BEVACIZUMAB FOR PREVENTION OF EARLY POSTVITRECTOMY HEMORRHAGE IN DIABETIC PATIENTS. Evidence-Based Ophthalmology, 2010, 11, 48-49.	0.0	0
431	Traitement de la r�tinopathie diab�tique. , 2010, , 111-141.		0
432	Anti-VEGF en las enfermedades inflamatorias. , 2010, , 101-106.		0
433	Intravitreal Bevacizumab for Macular Edema from Idiopathic Retinal Vasculitis, Aneurysms, and Neuroretinitis. Ophthalmic Surgery, Lasers and Imaging, 2010, , 1-3.	0.5	1
434	Proper Timing and Management of Vitreous Hemorrhage in Diabetic Patients. Highlights of Ophthalmology, 2011, 39, 6-10.	0.0	0
435	Tratamiento de las Hemorragias Intraoculares y de Otras Complicaciones. Highlights of Vitreoretina, 2012, 5, 4-10.	0.0	0
436	Use of intravitreal bevacizumab or triamcinolone acetonide as a preoperative adjunct to vitrectomy for vitreous haemorrhage in diabetics. Revista Brasileira De Oftalmologia, 2013, 72, 12-16.	0.1	3
437	Respuestas tisulares y vasculares en retinopat�a hipertensiva con anticuerpos monoclonales como terapia antiangiog�nica. Ciencia Y Tecnolog�a Para La Salud Visual Y Ocular, 2013, 11, 79.	0.1	0
438	The surgical management of diabetic retinopathy complications: An update. Egyptian Retina Journal, 2014, 2, 41.	0.2	1
439	Evaluaci�n y Manejo del Edema Macular Diab�tico. Highlights of Vitreoretina, 2015, 8, 2-12.	0.0	0

#	ARTICLE	IF	CITATIONS
440	Attenuation of corneal neovascularization by topical low-molecular-weight heparin-taurocholate 7 without bleeding complication. <i>International Journal of Ophthalmology</i> , 2016, 9, 1255-9.	0.5	1
441	COMPARATIVE EFFICACY OF LASER PHOTOCOAGULATION MONOTHERAPY, INTRAVITREAL BEVACIZUMAB MONOTHERAPY AND COMBINED LASER PHOTOCOAGULATION AND INTRAVITREAL BEVACIZUMAB THERAPY IN THE MANAGEMENT OF MACULAR OEDEMA \approx 350 μ m IN NONISCHAEMIC, NON-PROLIFERATIVE DIABETIC RETINOPATHY IN TYPE 2 DIABETES MELLITUS. <i>Journal of Evolution of Medical and Dental Sciences</i> , 2017, 6, 721-726.	0.1	0
442	Visual and Anatomical Outcomes after Single Injection of Intravitreal Bevacizumab (Avastin) in Patients with Diabetic Macular Edema. <i>Annals of International Medical and Dental Research</i> , 2017, 3, .	0.0	1
443	Rapid regression of retinal neovascularization following intravitreal bevacizumab in branch retinal vein occlusion imaged by optical coherence tomography angiography. <i>Indian Journal of Ophthalmology</i> , 2018, 66, 572.	0.5	1
444	Diabetes and the Eye. <i>Endocrinology</i> , 2018, , 231-273.	0.1	0
445	SAFETY AND EFFICACY OF PREOP INTRAVITREAL TRIAMCINOLONE PLUS BEVACIZUMAB COMBINATION AND BEVACIZUMAB ALONE IN VITREOUS SURGERY FOR NON-RESOLVING VITREOUS HAEMORRHAGE IN PROLIFERATIVE DIABETIC RETINOPATHY (PDR). <i>Journal of Evidence Based Medicine and Healthcare</i> , 2018, 4, 218-221.	0.0	0
446	Bevacizumab as an adjunct to vitrectomy for diabetic retinopathy: A retrospective study. <i>Egyptian Retina Journal</i> , 2018, 5, 6.	0.2	0
447	DIABETIC MACULAR EDEMA;. <i>The Professional Medical Journal</i> , 2018, 21, 810-815.	0.0	0
448	Diabetes and the Eye. <i>Endocrinology</i> , 2019, , 1-43.	0.1	0
449	Bevacizumab in Wet AMD treatment: A tribute to the thirteen years of experience from the beginning of the anti-VEGF era in Romania. <i>Experimental and Therapeutic Medicine</i> , 2019, 18, 4993-5000.	0.8	15
450	Diyabetik Makula \ddot{A} -deminde \ddot{A} ntravitreal Bevacizumab Tedavisinin Santral Makula Kal \ddot{A} nl \ddot{A} ± \ddot{A} ± Ve Santral Retina Duyarl \ddot{A} ±l \ddot{A} ± \ddot{A} ± \ddot{A} çezirine Etkisi. <i>Ege T\ddot{A}±p Bilimleri Dergisi</i> , 2020, 3, 59-66.	0.1	0
451	Anti-vegf therapy in treatment of vitreous hemorrhage due to proliferative diabetic retinopathy. <i>Ophthalmology Journal</i> , 2020, 13, 83-88.	0.1	0
452	Diabetes and the Eye. <i>Endocrinology</i> , 2020, , 231-273.	0.1	0
454	Novel Therapeutic Strategies For Posterior Segment Neovascularization. , 2008, , 445-526.		0
455	Is Diabetic Retinopathy an Inflammatory Disease? Inflammation as a Stimulus for Vascular Leakage and Proliferati on. <i>Essentials in Ophthalmology</i> , 2009, , 29-43.	0.0	0
456	Current concepts in targeted therapies for the pathophysiology of diabetic microvascular complications. <i>Vascular Health and Risk Management</i> , 2007, 3, 823-32.	1.0	33
457	Diabetic retinopathy: an update. <i>Indian Journal of Ophthalmology</i> , 2008, 56, 178-88.	0.5	35
458	Intravitreal bevacizumab as an adjunctive therapy before diabetic vitrectomy. <i>Clinical Ophthalmology</i> , 2008, 2, 709-16.	0.9	27

#	ARTICLE	IF	CITATIONS
459	Intravitreal bevacizumab: an analysis of the evidence. <i>Clinical Ophthalmology</i> , 2007, 1, 273-84.	0.9	8
460	Intravitreal bevacizumab treatment for retinal neovascularization and vitreous hemorrhage in proliferative diabetic retinopathy. <i>Clinical Ophthalmology</i> , 2007, 1, 149-55.	0.9	10
461	Age-related alterations in retinal neurovascular and inflammatory transcripts. <i>Molecular Vision</i> , 2011, 17, 1261-74.	1.1	28
462	Effects of bevacizumab on the neovascular membrane of proliferative diabetic retinopathy: reduction of endothelial cells and expressions of VEGF and HIF-1 α . <i>Molecular Vision</i> , 2012, 18, 1-9.	1.1	20
463	Overexpression of 15-lipoxygenase-1 in oxygen-induced ischemic retinopathy inhibits retinal neovascularization via downregulation of vascular endothelial growth factor-A expression. <i>Molecular Vision</i> , 2012, 18, 2847-59.	1.1	8
464	Study of 27 aqueous humor cytokines in patients with type 2 diabetes with or without retinopathy. <i>Molecular Vision</i> , 2013, 19, 1734-46.	1.1	78
465	Intravitreal bevacizumab as anti-vascular endothelial growth factor in the management of complications of proliferative diabetic retinopathy. <i>Medical Hypothesis, Discovery, and Innovation in Ophthalmology</i> , 2013, 2, 20-4.	0.4	10
466	Apelin in epiretinal membranes of patients with proliferative diabetic retinopathy. <i>Molecular Vision</i> , 2014, 20, 1122-31.	1.1	8
467	Multiplex bead array assay of plasma cytokines in type 2 diabetes mellitus with diabetic retinopathy. <i>Molecular Vision</i> , 2014, 20, 1137-45.	1.1	48
468	Characterization of cells from patient-derived fibrovascular membranes in proliferative diabetic retinopathy. <i>Molecular Vision</i> , 2015, 21, 673-87.	1.1	10
469	Single-dose Intravitreal Bevacizumab after Complete Panretinal Photocoagulation in Proliferative Diabetic Retinopathy: an Effective Adjunctive Treatment. <i>Medical Hypothesis, Discovery, and Innovation in Ophthalmology</i> , 2017, 6, 76-81.	0.4	4
470	New trends in intravitreal anti-VEGF therapy for ROP. <i>European Journal of Ophthalmology</i> , 2022, 32, 1340-1351.	0.7	7
471	Eales's Disease. , 2022, , 3179-3190.		0
472	Ocular complications with the use of radium-223: a case series. <i>Radiation Oncology</i> , 2022, 17, 97.	1.2	1
473	The Use of Vascular Endothelial Growth Factor Inhibitors in Patients with Proliferative Diabetic Retinopathy. <i>Oftalmologiya</i> , 2022, 19, 405-412.	0.2	0
474	Angiogenic footprints in diabetic retinopathy: opportunities for drug development. <i>Biotechnology and Genetic Engineering Reviews</i> , 2023, 39, 118-142.	2.4	5
476	Can the Future be Bright with Advances in Diabetic Eye Care?. <i>Endocrinology and Metabolism Clinics of North America</i> , 2022, , .	1.2	0
478	Vitreous hemorrhage " Causes, diagnosis, and management. <i>Indian Journal of Ophthalmology</i> , 2023, 71, 28.	0.5	8

#	ARTICLE	IF	CITATIONS
479	Anti-vascular endothelial growth factor for proliferative diabetic retinopathy. The Cochrane Library, 2023, 2023, .	1.5	3
480	Pre-operative intravitreal bevacizumab for tractional retinal detachment secondary to proliferative diabetic retinopathy: the Alvaro Rodriguez lecture 2023. International Journal of Retina and Vitreous, 2023, 9, .	0.9	0